EEF1A1 and cancer: For stage II cancer, the 5-year OS of patients with high EEF1A1 expression tended to be longer than that of patients with low EEF1A1 expression (89.0% vs. 71.1%, p = 0.051, HR = 2.68, 95% CI = 0.96–7.43).